Product
Avalglucosidase alfa
Aliases
avalglucosidase alfa, Avalglucosidase alfa (GZ402666), GZ402666
4 clinical trials
2 indications
Indication
Pompe's DiseaseIndication
Pompe DiseaseClinical trial
A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe DiseaseStatus: Completed, Estimated PCD: 2020-03-19
Clinical trial
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naïve Pediatric Participants With Infantile-Onset Pompe Disease (IOPD)Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical ResponseStatus: Active (not recruiting), Estimated PCD: 2019-09-30
Clinical trial
A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in FranceStatus: Active (not recruiting), Estimated PCD: 2024-12-31